These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab.
    Author: Chaudhary N, Ozer H, Huard D, Lightfoot S, Mesiya S.
    Journal: Dig Dis Sci; 2006 Apr; 51(4):775-8. PubMed ID: 16615002.
    Abstract:
    Helicobacter pylori infection is strongly associated with low-grade gastric lymphoma, commonly known as mucosa-associated lymphoid tissue (MALT) lymphoma. H. pylori eradication leads to complete remission in 80% of early stage MALT lymphomas. The treatment for early stage H. pylori-negative gastric MALT lymphoma is evolving. Rituximab, a chimeric anti-CD20 antibody, has shown response rates of approximately 50% with minimal toxicity in patients with B-cell non-Hodgkin lymphoma. We describe herein the clinical, endoscopic, and histologic features of a patient with H. pylori-negative gastric MALT lymphoma treated successfully with rituximab.
    [Abstract] [Full Text] [Related] [New Search]